Skip to content
Review

The redox paradox in neurological disorders: balancing cytoprotection, ferroptosis, and therapeutic targeting.

Sep 2026 · Brain Research · pp. 150528 · 1 citation · 208 references
Medicine

TL;DR

A contextual framework is built that specifies when HO-1 activation is protective versus detrimental, organised around three converging determinants: cell-type specificity, iron-handling capacity, and disease stage, which is extended to the often-overlooked dimensions of sex, age, and model heterogeneity, and used to interrogate conflicting findings across the literature.

Abstract

Neurological disorders, including ischaemic and haemorrhagic stroke, traumatic brain injury, and chronic neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis, represent a major global health burden. Despite diverse etiologies, these conditions share common pathological mechanisms driven by oxidative stress, neuroinflammation, mitochondrial dysfunction, iron dysregulation, and secondary neuronal injury. The nuclear factor erythroid 2-related factor 2 (Nrf2) signalling cascade and its downstream target heme oxygenase-1 (HO-1) are master regulators of cellular redox homeostasis. HO-1 plays a pivotal yet dichotomous role: its products biliverdin/bilirubin and carbon monoxide exert antioxidant, anti-inflammatory, and anti-apoptotic effects, whereas excessive HO-1 induction can exacerbate iron-mediated oxidative injury and ferroptosis through the release of redox-active ferrous iron. Rather than cataloguing protective studies, this review builds a contextual framework that specifies when HO-1 activation is protective versus detrimental, organised around three converging determinants: cell-type specificity, iron-handling capacity, and disease stage. We extend this framework to the often-overlooked dimensions of sex, age, and model heterogeneity, and use it to interrogate conflicting findings across the literature. We further dissect how Nrf2/HO-1 regulates ferroptosis through the GPX4-ACSL4-SLC7A11 axis, critically appraise the largely unexamined relationship between Nrf2 and the parallel FSP1/CoQ10, GCH1/BH4, and DHODH defence systems, and distil lessons from clinical trials of Nrf2 activators. The goal is an analytical account that identifies where the evidence is robust, where it is contradictory, and where the principal research gaps lie.

View source

Similar papers

Review Open access Sep 2026

Ferroptosis–neuroinflammation interplay: mechanistic pathways and therapeutic opportunities in central nervous system disorders

Understanding the mechanism of these players gives a mechanistic framework for the development of targeted therapeutic and nutritional interventions to reduce neuronal damage and help slow the progression of CNS disorders.

Khuzin Dinislam, V. A. Kataev, Mohammad Rehan Ajmal et al. · 0 citations
Review Open access Aug 2026

MicroRNA–Ferroptosis–Spinal Cord Injury: A Complex Interplay in Neurodegeneration and Repair

Current evidence on the molecular mechanisms linking miRNAs and ferroptosis in SCI is summarized, highlighting how miRNA-mediated regulation of ferroptosis contributes to neuronal death, glial responses, and impaired regeneration, and discusses emerging therapeutic strategies targeting this axis to promote neuroprotect...

Raju Poongodi, Tao-Hsiang Yang, Kuender D. Yang et al. · 0 citations
Review Sep 2026

Ferroptosis in Neurodegenerative Diseases: Iron Dysregulation, GPX4/FSP1 Signaling, and Emerging Neuroprotective Strategies.

INTRODUCTION Neurodegenerative Diseases (NDDs), including Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease (HD), and Multiple Sclerosis (MS), are increasingly associated with ferroptosis, a regulated irondependent form of cell death characterised by the exces...

Nainsi Kumari, Shruti Dwivedi, Satyam Yadav et al. · 0 citations
Review Aug 2026

Ferroptosis and Alzheimer's disease: Neuroimmune crosstalk and pharmacological opportunities.

Although available evidence supports an association between ferroptosis-related processes and AD pathobiology, no single marker is sufficient to establish ferroptosis in human AD tissue, which restricts the diagnostic and therapeutic interpretation of ferroptosis in AD.

Yelizaveta A. Marakhovskaya, A. Churov, Mikhail Arbatsky et al. · 0 citations
Review Aug 2026

Targeting ferroptosis and oxidative stress crosstalk: a new frontier in stroke neuroprotection

This review examines the molecular crosstalk between oxidative stress and ferroptosis in ischemia–reperfusion injury and summarizes key pharmacological and natural agents that target these pathways to achieve neuroprotection.

Wasim Akhtar, Mohd Muazzam Khan, Sanjay Kumar et al. · 0 citations
Review Open access Sep 2026

Ferroptosis in major depressive disorder: Molecular mechanisms, cellular vulnerability, and therapeutic opportunities

Major depressive disorder (MDD) is a heterogeneous psychiatric disorder involving oxidative stress, neuroinflammation, mitochondrial dysfunction, impaired neuroplasticity, and metabolic dysregulation. Ferroptosis, an iron-dependent form of regulated cell death driven by phospholipid peroxidation and antioxidant defense...

De-Yue Kong, Rui-Qi Duan, Xiang-Yu Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.